33results about How to "Reduce the likelihood of relapse" patented technology

Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

A sensor device for detecting product quality conditions is attached to each product to be delivered, and constant monitoring is performed on quality conditions of stock products in a storage room of a delivery center for quality assurance. For products in a storage room of a delivery truck, constant monitoring is also performed on quality conditions thereof in the same manner. If a quality abnormality is found in a product in the storage room, information regarding product sensing items and information regarding the current location of each delivery truck are processed to select a replacement stock product less susceptible to recurrence of a similar quality abnormality at the time of redelivery.

The invention relates to a source applicator for anal canal tumor radiotherapy, the source applicator comprises a cylindrical source applicator body of which the diameter is 3cm, wherein the front end of the source applicator body is a spherical arc, the front segment of the source applicator body is a right cylinder segment of which the length is 8.5cm, the right cylinder segment comprises the spherical arc at the front end, the rear segment of the source applicator body is bent in a manner of a 150-degree arc, the arc length of an introvert of an arc-shaped bent segment is 5cm, the source applicator body is internally and axially provided with three source applying tubes which are eccentrically arranged in a semicircle of the introvert side of the cross section of the source applicator body and distributed in a manner of a circular curve, and the distance between the center of each source applying tube and the outer wall of the introvert side of the source applicator body is 5.5cm; an arc between the circle center of the first source applying tube and the circle center of the second source applying tube is equal to an arc between the circle center of the second source applying tube and the circle center of the third source applying tube, and a central angle corresponding to the arc is 60 degrees. The source applicator has a good radiotherapy effect on nidus that part carcinoma of the anal canal spreads outside the anus edge, reduces the possibility of tumor recurrence and facilitates radical cure of the tumor.

The present invention provides CD19 and CD30 dual-target chimeric antigen receptors and applications thereof. The chimeric antigen receptors include antigen binding domains, transmembrane domains and signal transduction domains; the antigen binding domains include Anti-CD19 single-chain antibody and anti-CD30 single-chain antibody. The anti-CD19 and CD30 dual-target chimeric antigen receptor of the present invention has targeting activity on CD19-positive and / or CD30-positive cells, and the T cells expressing anti-CD19 and CD30 dual-target chimeric antigen receptor have the expression level of CD19 antigen Tumor cells with little or no expression and tumor cells with little or no expression of CD30 antigen all have a killing effect, which is beneficial to avoid immune escape and reduce the possibility of disease recurrence.

The invention discloses a method for preparing an anti-methamphetamine yolk antibody, belonging to the field of drugs for detoxification. The preparation method of the yolk antibody against methamphetamine comprises: immunizing laying hens with methamphetamine-bovine serum albumin antigen, collecting eggs laid by the laying hens after immunization, extracting and purifying the The egg yolk antibody in eggs, the obtained egg yolk antibody is anti-methamphetamine egg yolk antibody. The anti-methamphetamine egg yolk antibody, the specific anti-methamphetamine egg yolk antibody can first neutralize the free methamphetamine in the patient's blood, thereby reducing the amount of methamphetamine entering the patient's central nervous system, and further reducing the amount of methamphetamine. The toxicity of amphetamine to neurons in the brain. At the same time, the anti-methamphetamine egg yolk antibody can be used as a drug molecule receptor blocker, which can prevent the positive reinforcement of drugs to a certain extent, thereby diluting the patient's psychological desire and reducing Patient's likelihood of relapse.

The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.

The present invention relates to a pharmaceutical composition for the treatment or prevention of breast cancer / breast cancer, in particular locally recurrent or metastatic breast cancer, in a patient or group of patients suffering from or suspected of suffering from breast cancer, comprising: at least 4 to 8 HLA-A tumor antigen peptides corresponding to the MHC class I complex and at least 2 tumor antigen peptides corresponding to the MHC class II complex, wherein the HLA tumor antigen peptide is a tumor-specific or tumor-associated HLA antigen peptide and is directed to at least one MHC complex, including combinations thereof; pharmaceutical compositions, kits (or portions thereof); methods of determining class I and / or class II HLA peptides; a process for preparing the pharmaceutical composition according to the invention; the invention also relates to application of the pharmaceutical composition in preparation of the pharmaceutical composition for treating malignant tumors, leukemia and tumors.